The teachings of Long COVID

  • Nisreen A. Alwan
Comment

Announcements

  • We post news about the journal and exciting new research from across medicine and public health.

  • Interested in meeting our editors, organizing a virtual site visit, and/or discussing a manuscript in preparation? Click the link above to find out more.

Advertisement

  • Mascheroni et al. develop a method for individual clinical predictions by combining mathematical modelling and machine learning in a Bayesian framework (BaM3). By using both synthetic and real clinical datasets, they show the potential of the method to predict tumour growth in the context of clinical data sparsity and limited knowledge of disease mechanisms.

    • Pietro Mascheroni
    • Symeon Savvopoulos
    • Haralampos Hatzikirou
    Article Open Access
  • KRAS is one of the most commonly mutated oncogenes in lung cancer but has long been considered undruggable. With the recent FDA approval of sotorasib, supported by positive phase II trial data now published in The New England Journal of Medicine, this is no longer the case.

    • Ben Abbott
    Research Highlight Open Access
  • Dengue virus is transmitted by Aedes aegypti mosquitoes and causes the disease known as dengue. In a trial published in The New England Journal of Medicine, Utarini and colleagues report that release of wolbachia-infected A. aegypti populations in a dengue endemic area reduces the number of symptomatic cases and of hospitalisations.

    • Andreia Cunha
    Research Highlight Open Access
  • De Salazar et al. quantify the impact of BNT162b2 mRNA vaccination on COVID-19 transmission and deaths in residents of long-term care facilities in Catalonia, Spain using statistical modelling. They find that high vaccination coverage results in a substantial reduction in transmission amongst residents, preventing around 3 in 4 documented infections and COVID-19-related deaths.

    • Pablo M. De Salazar
    • Nicholas B. Link
    • Mauricio Santillana
    Article Open Access
  • Wagner et al. carry out a longitudinal seroepidemiological study of SARS-CoV-2 antibodies in a cohort of adults from a large company in Vienna, Austria. In individuals positive for S1-reactive antibodies at baseline, RBD-specific antibodies are most likely to persist for six months and correlate most closely with SARS-CoV-2 neutralizing ability.

    • Angelika Wagner
    • Angela Guzek
    • Ursula Wiedermann
    Article Open Access
  • Alwan discusses the lessons learnt over the past year regarding Long COVID, prolonged illness resulting from SARS-CoV-2 infection, and their implications for public health policy and disease management, drawing insight form her own lived experience, research, and advocacy work with Long COVID.

    • Nisreen A. Alwan
    Comment Open Access